Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab.

C, Voors-Pette; K, Lebozec; P, Dogterom; L, Jullien; P, Billiald; P, Ferlan; L, Renaud; O, Favre-Bulle; G, Avenard; M, Machacek; Y, Plétan; M, Jandrot-Perrus

doi:10.1161/atvbaha.118.312314

Public

Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab.

Shared by NobleBlocks on May 1, 2019 • 12:00 AM UTC

Authors:

Voors-Pette C

Lebozec K

Dogterom P

Abstract

Objective- ACT017 is a novel, first in class, therapeutic antibody to platelet GPVI (glycoprotein VI) with potent and selective antiplatelet effects. This first-in-human, randomized, placebo-controlled phase 1 study was conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacody...

Subject

Safety

Pharmacokinetics

Pharmacodynamics

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!